Susan Quinn

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non–Small-Cell Lung Cancer

Lecia V. Sequist, Benjamin Besse, Thomas J. Lynch et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Oncology, Pharmacology +16

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Kwok-K. Wong, Paula M. Fracasso, Ronald M. Bukowski et al. · Clinical Cancer Research · 2009 · 303 citations · Full text

Medicine, Oncology, Pharmacology +13

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Charles Erlichman, Manuel Hidalgo, Joseph Boni et al. · Journal of Clinical Oncology · 2006 · 148 citations · Full text

Medicine, Oncology, Pharmacology +9

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

A.R. Abdul Razak, Denis Soulières, Scott A. Laurie et al. · Annals of Oncology · 2012 · 103 citations

Medicine, Oncology, Pharmacology +16

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer

J. Corral, Tony Mok, Kazuhiko Nakagawa et al. · Future Oncology · 2019 · 38 citations · Full text

Pharmacy, Oncology, Pharmacology +17